TWiV 1244: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses Vijay Prasad’s return to the FDA, revoking of COVID vaccine authorization for young children, the Legionnaires’ outbreak in Harlem, the new labeling requirements for Ixchiq, the infectious attenuated Chikungunya vaccine and the importation of H5 influenza virus in Antarctica, before Dr. Griffin deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, guidelines for treating COVID-19, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, the association of “virus rebound” and post-acute sequelae among hospitalized patients, how virus infection particularly influenza and SARS-CoV-2 may ‘re-activate’ dormant cancer cells and contacting your federal government representative to stop the assault on science and biomedical research.

Subscribe (free): Apple Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Prasad returns to the FDA (Washington Post)
• Pfizer Covid vaccine for young children may not be renewed by FDA (The Guardian)
• Report suggests FDA may not reauthorize Pfizer COVID vaccine for young kids (CIDRAP)
• Factors Associated With Pediatric COVID-19 Mortality: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study (Journal of Pediatric Infectious Diseases Society)
• Legionnaires’ Disease: In Harlem (NYC Health)
• Recommended Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated (FDA)
• FDA Removes Recommended Pause in Use and Approves Required Updated Labeling (FDA)
• Chikungunya Vaccines (CDC: Chikungunya virus)
• Chikungunya in China (CDC: Travelers’ Health)
• Travelers’ health notices (CDC: Travelers’ Health)
• Areas at Risk for Chikungunya (CDC: Chikungunya virus)
• Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged ≥50 years (CID)
• Tracking HPAIV H5 through a geographic survey of Antarctic seabird populations
• (Scientific Reports)
• Report details first suspected H5 avian flu detections in seabirds in Antarctica(CIDRAP)
• Wastewater for measles (WasterWater Scan)
• Measles cases and outbreaks (CDC Rubeola)
• Measles vaccine recommendations from NYP (jpg)
• Weekly measles and rubella monitoring (Government of Canada)
• Measles (WHO)
• Get the FACTS about measles (NY State Department of Health)
• Measles (CDC Measles (Rubeola))
• Presumptive evidence of measles immunity (CDC)
• Contraindications and precautions to measles vaccination (CDC)
• Measles (CDC Measles (Rubeola))
• Adverse events associated with childhood vaccines: evidence bearing on causality (NLM)
• Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America)
• Deaths following vaccination: what does the evidence show (Vaccine)
• Influenza: Waste water scan for 11 pathogens (WastewaterSCan)
• US respiratory virus activity (CDC Respiratory Illnesses)
• Respiratory virus activity levels (CDC Respiratory Illnesses)
• Weekly surveillance report: clift notes (CDC FluView)
• FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA)
• RSV: Waste water scan for 11 pathogens (WastewaterSCan)
• US respiratory virus activity (CDC Respiratory Illnesses)
• ENFLONSIA: novel drug approvals 2025 (FDA)
• RSV-Network (CDC Respiratory Syncytial virus Infection)
• Waste water scan for 11 pathogens (WastewaterSCan)
• COVID-19 deaths (CDC)
• Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses)
• COVID-19 national and regional trends (CDC)
• 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness (CID)
• COVID-19 variant tracker (CDC)
• SARS-CoV-2 genomes galore (Nextstrain)
• Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV)
• Where to get pemgarda (Pemgarda)
• EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
• Infusion center (Prime Fusions)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Drug interaction checker (University of Liverpool)
• Paxlovid (Pfizer)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What to do when sick with a respiratory virus (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Daniel Griffin’s evidence based medical practices for long COVID (OFID)
• Long COVID hotline (Columbia : Columbia University Irving Medical Center)
• The answers: Long COVID
• TWiV 1243: Capitalism, COVID and Cancer (MicrobeTV)
• Respiratory viral infections awaken metastatic breast cancer cells in lungs(Nature)
• Reaching out to US house representative
• Letters read on TWiV 1244
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene Ramsey. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

Content in this podcast should not be construed as medical advice.